Aktuelle News
News Funktionen
Weitere Funktionen
10 Juli 2015
Genmab A/S
Major Shareholder Announcement
9 Juli 2015
Genmab A/S
Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
7 Juli 2015
Genmab A/S
Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
23 Juni 2015
Genmab A/S
Articles of Association for Genmab A/S
11 Juni 2015
Genmab A/S
Grant of Warrants to Genmab Employees
5 Juni 2015
Genmab A/S
Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA
2 Juni 2015
Genmab A/S
Genmab to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
Genmab A/S
Genmab Gains License to Antibody Panel Targeting CD19
1 Juni 2015
Genmab A/S
Ofatumumab Included in Regulatory Submission to US Authorities from Gilead
29 Mai 2015
Genmab A/S
Genmab’s Total Number of Voting Rights and Total Share Capital
22 Mai 2015
Genmab A/S
Articles of Association for Genmab A/S
21 Mai 2015
Genmab A/S
Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA
20 Mai 2015
Genmab A/S
Report Pursuant to Section 28a of the Danish Securities Trading Act
Genmab A/S
Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015
19 Mai 2015
Genmab A/S
Genmab Enters Commercial DuoBody® Technology Agreement with BioNTech in Field of Immuno-oncology
13 Mai 2015
Genmab A/S
HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting
12 Mai 2015
Genmab A/S
Genmab Announces Financial Results for the First Quarter of 2015
6 Mai 2015
Genmab A/S
First Quarter 2015 Net Sales Figures for Arzerra® (Ofatumumab)
27 April 2015
Genmab A/S
Genmab Announces Phase III Study of Arzerra® Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
16 April 2015
Genmab A/S
Genmab Achieves USD 10 Million Milestone in Daratumumab Collaboration with Janssen
1 April 2015
Genmab A/S
Articles of Association for Genmab A/S
31 März 2015
Genmab A/S
Genmab’s Total Number of Voting Rights and Total Share Capital
26 März 2015
Genmab A/S
Report Pursuant to Section 28a of the Danish Securities Trading Act
Genmab A/S
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to two Board Members and Grant of Warrants to Employees in Genmab
Genmab A/S
Passing of Genmab A/S’ Annual General Meeting
18 März 2015
Genmab A/S
Genmab Acquires Antibody Assets from iDD Biotech
16 März 2015
Genmab A/S
Genmab Retains Partial Rights for HuMax-TAC-ADC – Will Not Exercise Co-development Right
12 März 2015
Genmab A/S
Articles of Association for Genmab A/S
Genmab A/S
Report Pursuant to Section 28a of the Danish Securities Trading Act
11 März 2015
Genmab A/S
Report Pursuant to Section 28a of the Danish Securities Trading Act